News Releases

Oct 01, 2020
Akouos Announces Key Leadership Appointments
BOSTON, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, announced the appointment of Sachiyo Minegishi as chief financial officer,
Additional Formats
Sep 24, 2020
Akouos to Present at Upcoming October Virtual Investor Conferences
BOSTON, Sept. 24, 2020 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that Manny Simons, Ph.D., M.B.A., CEO, President and
Additional Formats
Sep 08, 2020
Akouos to Present at Cantor Global Virtual Healthcare Conference
BOSTON, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that Manny Simons, Ph.D., M.B.A., CEO, President and
Additional Formats
Aug 05, 2020
Akouos Announces Expansion of Executive Team and Board of Directors
Alan Smith, Ph.D., Joins as Chief Technology Officer Saira Ramasastry Joins Board of Directors; Arthur Tzianabos, Ph.D., Role Expanded to Chairman BOSTON, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (Nasdaq: AKUS), a precision genetic medicine company dedicated to developing potential
Additional Formats
Aug 03, 2020
Akouos to Present at BTIG Virtual Biotechnology Conference
BOSTON , Aug. 03, 2020 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for people worldwide who live with disabling hearing loss, today announced that Manny Simons , Ph.D., M.B.A., CEO, President and
Additional Formats
Jun 30, 2020
Akouos Announces Closing of Initial Public Offering
BOSTON , June 30, 2020 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (Nasdaq: AKUS), a precision genetic medicine company dedicated to developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for people worldwide who live with disabling hearing
Additional Formats
Jun 25, 2020
Akouos Announces Pricing of Initial Public Offering
BOSTON, June 25, 2020 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (Nasdaq: AKUS), a precision genetic medicine company dedicated to developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for people worldwide who live with disabling hearing
Additional Formats
Displaying 1 - 10 of 14